Naloxone fails to produce conditioned place aversion in mu-opioid receptor knock-out mice

Neuroscience. 2001;106(4):757-63. doi: 10.1016/s0306-4522(01)00333-5.

Abstract

There is growing evidence that tonic activity of the opioid system may be important in the modulation of affective state. Naloxone produces a conditioned place aversion in rodents, an effect that is centrally mediated. Previous pharmacological data using antagonists with preferential actions at mu-, delta-, and kappa-opioid receptors indicate the importance of the mu-opioid receptor in mediating this effect. We sought to test the mu-opioid receptor selectivity of naloxone aversion using mu-opioid receptor knock-out mice. mu-Opioid receptor knock-out and wild-type mice were tested for naloxone (10 mg/kg, s.c.) aversion using a place conditioning paradigm. As a positive control for associative learning, knock-out mice were tested for conditioned place aversion to a kappa agonist, U50,488H (2 mg/kg, s.c.). Naloxone produced a significant place aversion in wild-type mice, but failed to have any effect in mu-opioid receptor knock-out mice. On the other hand, both knock-out and wild-type mice treated with U50,488H spent significantly less time in the drug-paired chamber compared to their respective vehicle controls. We conclude that the mu-opioid receptor is crucial for the acquisition of naloxone-induced conditioned place aversion. Furthermore, in a separate experiment using C57BL/6 mice, the delta-selective antagonist naltrindole (10 or 30 mg/kg, s.c.) failed to produce conditioned place aversion.Taken together, these data further support the notion that naloxone produces aversion by antagonizing tonic opioid activity at the mu-opioid receptor.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer / pharmacology
  • Analgesics, Non-Narcotic / pharmacology
  • Animals
  • Avoidance Learning / drug effects
  • Avoidance Learning / physiology*
  • Brain / drug effects
  • Brain / metabolism*
  • Conditioning, Psychological / drug effects
  • Conditioning, Psychological / physiology*
  • Dose-Response Relationship, Drug
  • Habituation, Psychophysiologic / drug effects
  • Habituation, Psychophysiologic / physiology
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Mice, Knockout
  • Motor Activity / drug effects
  • Motor Activity / physiology
  • Naloxone / pharmacology*
  • Naltrexone / analogs & derivatives*
  • Naltrexone / pharmacology
  • Narcotic Antagonists / pharmacology*
  • Neurons / drug effects
  • Neurons / metabolism
  • Opioid Peptides / antagonists & inhibitors
  • Opioid Peptides / metabolism*
  • Phenotype
  • Receptors, Opioid, delta / drug effects
  • Receptors, Opioid, delta / metabolism
  • Receptors, Opioid, kappa / drug effects
  • Receptors, Opioid, kappa / metabolism
  • Receptors, Opioid, mu / deficiency*
  • Receptors, Opioid, mu / genetics
  • Synaptic Transmission / drug effects
  • Synaptic Transmission / physiology

Substances

  • Analgesics, Non-Narcotic
  • Narcotic Antagonists
  • Opioid Peptides
  • Receptors, Opioid, delta
  • Receptors, Opioid, kappa
  • Receptors, Opioid, mu
  • Naloxone
  • Naltrexone
  • 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer
  • naltrindole